Aarti Drugs Limited has released its audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated revenue from operations of ₹2,56,531 lakhs for the financial year, alongside a net profit attributable to owners of ₹19,492 lakhs. Furthermore, the company announced strategic re-appointments for audit services and the re-constitution of its Risk Management Committee to enhance corporate governance and oversight.
Financial Performance Summary
For the fiscal year ending March 31, 2026, Aarti Drugs Limited demonstrated consistent growth in its consolidated operations. The company achieved an annual consolidated revenue of ₹2,56,531 lakhs, compared to ₹2,38,703 lakhs in the previous year. The net profit attributable to the owners of the company reached ₹19,492 lakhs, reflecting the company’s operational efficiency in the competitive pharmaceutical landscape. The results were reviewed by the Audit Committee and approved by the Board of Directors on May 15, 2026.
Strategic Re-appointments
The company has confirmed the re-appointment of key professional firms to ensure continuity in financial oversight. M/s GMVP & Associates LLP has been re-appointed as the Cost Auditor for the 2026-27 financial year. Additionally, M/s Raman S. Shah & Co. has been re-appointed as the Internal Auditor for a period of three consecutive years, effective from April 1, 2026.
Board and Committee Updates
As part of its commitment to robust corporate governance, the company has re-constituted its Risk Management Committee. The committee now includes Shri Narendra J. Salvi, a Non-Executive, Non-Independent Director, as a member, effective May 15, 2026. This move is intended to strengthen the board’s risk assessment and mitigation framework across the organization’s diverse pharmaceutical operations.
Source: BSE
